Pharmaceuticals News and Research

RSS

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals, Inc. today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma.

11 Nov 2009

Healthpoint to launch ULTRACEPT Antiseptic Handwash

A new antiseptic handwash, based on a formula previously used only by surgeons and other clinicians, will soon be available to consumers and provides up to six hours of prolonged germ kill with repeated use.

11 Nov 2009

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Poniard Pharmaceuticals, Inc. today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

Particle Sciences expands operations by acquiring new additional space

Particle Sciences Inc., a leading pharmaceutical CRO, has further expanded their capabilities by the acquisition of additional space bringing their total to approximately 21,000 sq ft.

11 Nov 2009

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).

11 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Pfizer and BMP Sunstone team up to promote Depo-Provera, a product for treating endometriosis

Pfizer China and BMP Sunstone Corporation today announced a strategic partnership to exclusively import, distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China. Endometriosis is a medical condition in women of childbearing age that can cause significant pain.

11 Nov 2009

Mylan subsidiary receives FDA approval for its Lansoprazole DR Capsules ANDA

Mylan Inc. today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) Capsules, 15 mg and 30 mg. This product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.

11 Nov 2009

Negative and positive emotions have a direct impact on pain, says new study

Getting a flu shot this fall? Canadians scientists have found that focusing on a pretty image could alleviate the sting of that vaccine. According to a new Universit- de Montr-al study, published in the latest edition of the Proceedings of the National Academy of Sciences (PNAS), negative and positive emotions have a direct impact on pain.

11 Nov 2009

Westaim executes amalgamation agreement with NUCRYST Pharmaceuticals

The Westaim Corporation today announced the execution of an amalgamation agreement with NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS). Under the agreement, NUCRYST will amalgamate with a newly-formed, wholly-owned subsidiary of Westaim.

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

SMI Manufacturing to invest $10 million in HealthSport

HealthSport, Inc., the preeminent formulator and developer of edible, multi-layer film strips that deliver drug and dietary supplement actives through buccal and sublingual absorption as well as oral ingestion, announced today that its strategic manufacturing partner, SMI Manufacturing, has agreed to invest $10 million into HealthSport.

11 Nov 2009

Teva Pharmaceutical's generic lansoprazole does not infringe patent No. 5,464,632: U.S. Court

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid® (Lansoprazole) SoluTab.

10 Nov 2009

Colorcon acquires exclusive rights to market ARmark's micro-tag authentication technology

ARmark Authentication Technologies, LLC, and Colorcon, Inc. announced today an alliance in the development and introduction of ®mark® On-Dose ID(TM), an authentication technology that incorporates microscopic covert micro-tags into the immediate-release film coatings of solid oral dosage forms (SODFs) to prevent counterfeiting.

10 Nov 2009

Cerimon Pharmaceuticals acquires rights to develop and commercialize diclofenac sodium patch in Europe

Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in Europe, including most countries in the European Union, Turkey, Switzerland, Norway, the Balkan countries and Iceland. Terms of the agreement were not disclosed. Cerimon initially acquired the U.S. rights to develop and commercialize the patch formulation of diclofenac in 2005.

10 Nov 2009

U.S. DOD grant to study vigabatrin in combination with opiates to manage pain

Catalyst Pharmaceutical Partners, Inc. today reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a $1.2 million grant from the U.S. Department of Defense (DOD) to conduct an animal study of the use of vigabatrin in combination with opiates to effectively manage pain while reducing the potential for opiate addiction.

10 Nov 2009

Six universities aim to expand drug access in developing countries

Six universities have agreed to an effort to "encourage companies to give poor countries better access to drugs and medical products stemming from discoveries made on their campuses," Bloomberg reports (Lauerman, 11/9).

10 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

Javelin Pharmaceuticals announces financial results for the third quarter of 2009

Javelin Pharmaceuticals, Inc., a leading developer of novel acute care pain products, today reported its unaudited financial results for the third quarter ended September 30, 2009.

10 Nov 2009

Pharmaceuticals News and Research

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Healthpoint to launch ULTRACEPT Antiseptic Handwash

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Particle Sciences expands operations by acquiring new additional space

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

Pfizer and BMP Sunstone team up to promote Depo-Provera, a product for treating endometriosis

Mylan subsidiary receives FDA approval for its Lansoprazole DR Capsules ANDA

Negative and positive emotions have a direct impact on pain, says new study

Westaim executes amalgamation agreement with NUCRYST Pharmaceuticals

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

SMI Manufacturing to invest $10 million in HealthSport

Teva Pharmaceutical's generic lansoprazole does not infringe patent No. 5,464,632: U.S. Court

Colorcon acquires exclusive rights to market ARmark's micro-tag authentication technology

Cerimon Pharmaceuticals acquires rights to develop and commercialize diclofenac sodium patch in Europe

U.S. DOD grant to study vigabatrin in combination with opiates to manage pain

Six universities aim to expand drug access in developing countries

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Javelin Pharmaceuticals announces financial results for the third quarter of 2009

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring